Professional Documents
Culture Documents
Overview of Biotechnology at The End of The 20th Century
Overview of Biotechnology at The End of The 20th Century
Modern biotechnology began when recombinant human insulin was first marketed in
the United States in 1982. The effort leading up to this landmark event began in the
early 1970's when research scientists developed protocols to construct vectors, by
cutting out and pasting pieces of DNA together to create a new piece of DNA
(recombinant DNA), that could be inserted into the bacterium, Escherichia coli
(transformation). If one of the pieces of the new DNA included a gene which
produced a protein enzyme that broke down a particular antibiotic, the bacterium
would be resistant to that antibiotic and could grow in a medium containing it. To the
piece of DNA that conferred resistance of Escherichia coli to a particular antibiotic
was added the human gene for the making of insulin. If this recombinant DNA
containing the human insulin gene was used to transform Escherichia coli, and the
bacteria were plated on an agar plate containing the antibiotic, the bacteria that grew
contained not only the antibiotic resistant gene but also the insulin gene. Additional
new pieces of DNA were then added to promote the expression of the human insulin
gene so that this new recombinant DNA (expression vector) could be used to
transform Escherichia coli. Thus, large quantities of human insulin messenger RNA
were formed, which in turn were translated into large quantities of the human insulin
protein. This story of the beginning of modern biotechnology represents the research
piece of modern biotechnology. Biotechnology Research is the topic of BT210
(Biotechnology Experience I: Research) which together with this course, comprises
the Certificate in Biotechnology at NHCTC.
The next step in the development of modern biotechnology methods of protein
production is what is now called process development. During process development
the best growth conditions are identified that produce the most protein, as efficiently
as possible. This best process is scaled-up to produce the quantities of human protein
that are needed for pre-clinical and clinical trials and for manufacture. Process
development also includes the development of media, buffers, reagents, solutions,
and assays and the choice of tools, such as bioreactors and liquid chromatography
equipment, for the growth of recombinant cells (upstream processing), for the
isolation and purification of the recombinant protein (downstream processing), and
for tests to insure that both the upstream and downstream processes are proceeding in
a predictable manner (quality control). Toward the end of process development a
master cell bank is laid down. The master cell bank is sized to last as long as the
manufacture of the product will take place. Ordinarily the master cell bank is a large
quantity of vials each containing 1ml of media within which there are about
1,000,000 recombinant cells (1,000,000 cells/ml) which are stored frozen in liquid
nitrogen.
Since the manufacture of human insulin using recombinant Escherichia coli began in
1982, many other proteins (for human and veterinary therapeutics, vaccines and
diagnostics) are being manufactured. Today, 24 human therapeutic or vaccine
proteins made by modern biotechnology methods have been approved by the FDA for
marketing. This is the list and date of approval by the FDA: Actimmune (1990),
Activase (1990), Alferon N (1989), Betaseron (1993), Cerezyme (1994), Engerix-B
(1989), EPOGEN (1993), PROCRIT (1993), Humatrope (1987), Humulin (1987),
Intron A (1986-1992), KoGENate (1993), Leukine (1991), NEUPOGEN (1994),
Nutropin (1994), OncoScint (1992), ORTHOCLONE (1993), Proleukin (1992),
Protropin (1985), Pulmozyme (1993), RECOMBINATE (1992) RECOMBIVAX HB
(1986), ReoPro (1994), Roferon-A (1986-1988) There are more than 200 other
human therapeutic and vaccine proteins in clinical trials. Products are being tested to
target the following diseases: cancer, AIDS, heart disease, multiple sclerosis,
rheumatoid arthritis and viral diseases. Products are also being developed to reduce
bleeding from surgical procedures, aid in wound healing and prevent organ transplant
rejection. Vaccines are also being developed to prevent Lyme disease and herpes and
against AIDS, rheumatoid arthritis, and cancer.
It is difficult to predict the future of this exciting new field of modern biotechnology
using recombinant DNA to produce proteins. One direction the field seems to be
moving, at least at the research level, is toward the synthesis of smaller molecules
that are closer to organic chemicals than biochemicals, but contain the same or better
activity compared to the native protein.
The student should realize that the education and training obtained in this course
could be used in a number of fields including bioprocessing without the use of
recombinant DNA and chemical processing. This is known as cross-training.
EDUCATIONAL RESOURCES
ON-LINE COURSES
These are University level engineering courses in Bioprocessing and are well worth
investigating for presentation of material and content.
Sartorius Biotechnology
On this page is an interactive process chain diagram. Although the links on the
diagram are related to products sold by the company, it is a good example of a flow
chart for a bio-system.
Biotechnology
This web site is an "Information Resource" from the National Agricultural Library of
the US Department of Agriculture. It is no longer updated, but most of the links
included are still active. It is a list of selected sources, services and publications
covering many aspects of agricultural biotechnology. The page has no stand-alone
information, but is a good resource.
PHRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the
country's leading research-based pharmaceutical and biotechnology companies.
Phrma is decidedly pro-industry in their outlook. This site has information on the
drug industry and federal, state policies. They address such public policy issues as
the cost of pharmaceuticals. The site also has information on genomics,
bioinformatics and other related topics about modern biotechnology.
PROFESSIONAL SOCIETIES/ORGANIZATIONS
SUPPLIERS
Millipore Corporation
Millipore is a manufacturer of filtration devices and filters for research as well as
industry. The Biotech and Pharmaceutical section of this web site focuses on
industrial applications that include downstream processing and water purification.
They include some flow charts for examples of industrial processes such as beer
brewing. Many of their products consider the need for quality control and assurance.
They also describe much of the terminology that accompanies filters and filter
selection.
NEW BRUNSWICK SCIENTIFIC CO., INC.
New Brunswick is a manufacturer of cell culture bioreactors, shakers, fermentors and
other fermentation and bioprocessing equipment. They also have an on-line technical
library that is a must for anyone interested in this area. Their technical literature
includes theoretical basics and specifics about setting up cultures.
The mission of the Biological Process Technology Institute is to educate and train
advanced students and to conduct innovative research at the interface of biology and
engineering.
BIOREMEDIATION
Bioremediation Resources
This is a list of resources compiled by the Biotechnology Information Center. BIC is
maintained by the National Agricultural Library of the US Department of Agriculture
and provides access to selected sources, services and publications covering many
aspects of agricultural biotechnology. The site is composed of links that take you to
resources both public and private.